Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of a combination of Xuebijing and thymosin α1 on patients with severe pneumonia complicated with sepsis, and its influence on serum inflammatory factors

Yan Li, Suhang Wang, Jing Zhang, Jie Cao

Department of Respiratory and Critical Care, Tianjin Medical University General Hospital, Tianjin 300052, China;

For correspondence:- Jie Cao Email: caojiedr123@outlook.com

Accepted: 13 June 2022 Published: 31 July 2022

Citation: Li Y, Wang S, Zhang J, Cao J. Effect of a combination of Xuebijing and thymosin α1 on patients with severe pneumonia complicated with sepsis, and its influence on serum inflammatory factors. Trop J Pharm Res 2022; 21(7):1507-1513 doi: 10.4314/tjpr.v21i7.22

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the influence of a combination of Xuebijing and thymosin α1 on acute and septic bronchopneumonia (ASB) patients, and the effect of the treatment on inflammation.

Methods: Eighty-one (81) ASB patients admitted to Tianjin Medical University General Hospital, Tianjin, China from January 2015 to July 2019 were enrolled in the study. The patients were assigned to control group (n = 41) and a study group (n = 40). The control patients were treated with Xuebijing injection, i.v., while the study group received a combination of Xuebijing injection and thymosin α1 via the subcutaneous route. Patients’ body temperature, heartbeat, white blood cell count, as well as other parameters, including blood gas indices, serum concentrations of IL-6, TNF-α and C-reactive protein (CRP), as well as well as blood gas indices were determined by enzyme-linked immunosorbent assay (ELISA). Bacterial clearance and therapeutic effectiveness were evaluated pre- and post-treatment.

Results: Post-therapy basal temperature, breathing, heartbeat, number of white blood cells and other indices decreased in study patients, relative to control (p < 0.05). Moreover, the levels of hydrogen ion concentration (pH) and arterial carbon dioxide partial pressure (PaCO₂) were significantly lower in study group than in control group (p < 0.05). Patients in the study group had lower serum levels of IL-6, TNF-α and CRP, when compared to control group, while bacterial load was significantly reduced in study subjects, relative to controls (p < 0.05).

Conclusion: Combined use of thymosin α1 and Xuebijing is significantly effective in the management of patients suffering from ASB. The combination therapy also improves the hemorheological status of patients. Thus, it is a potential therapeutic strategy for ASB.

Keywords: Acute bronchopneumonia, Xuebijing, Thymosin ?1, Septicemia, Inflammation